Dermatomyositis - Pipeline Review, H1 2016 Summary Global Markets Direct's, 'Dermatomyositis - Pipeline Review, H1 2016', provides an overview of the Dermatomyositis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Dermatomyositis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Dermatomyositis and features dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape of Dermatomyositis - The report reviews pipeline therapeutics for Dermatomyositis by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved Dermatomyositis therapeutics and enlists all their major and minor projects - The report assesses Dermatomyositis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news related to pipeline therapeutics for Dermatomyositis Reasons To Buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for Dermatomyositis - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Dermatomyositis pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2 List of Tables 4 List of Figures 4 Introduction 5 Global Markets Direct Report Coverage 5 Dermatomyositis Overview 6 Therapeutics Development 7 Pipeline Products for Dermatomyositis - Overview 7 Dermatomyositis - Therapeutics under Development by Companies 8 Dermatomyositis - Pipeline Products Glance 9 Clinical Stage Products 9 Early Stage Products 10 Dermatomyositis - Products under Development by Companies 11 Dermatomyositis - Companies Involved in Therapeutics Development 12 F. Hoffmann-La Roche Ltd. 12 Hope Pharmaceuticals, Inc. 13 Idera Pharmaceuticals, Inc. 14 MedImmune, LLC 15 Neovacs SA 16 Novartis AG 17 Dermatomyositis - Therapeutics Assessment 18 Assessment by Monotherapy Products 18 Assessment by Target 19 Assessment by Mechanism of Action 21 Assessment by Route of Administration 23 Assessment by Molecule Type 25 Drug Profiles 27 IMO-8400 - Drug Profile 27 Product Description 27 Mechanism of Action 27 R&D Progress 27 JBT-101 - Drug Profile 29 Product Description 29 Mechanism of Action 29 R&D Progress 29 MEDI-7734 - Drug Profile 31 Product Description 31 Mechanism of Action 31 R&D Progress 31 siponimod - Drug Profile 32 Product Description 32 Mechanism of Action 32 R&D Progress 32 sodium thiosulfate - Drug Profile 34 Product Description 34 Mechanism of Action 34 R&D Progress 34 tocilizumab - Drug Profile 35 Product Description 35 Mechanism of Action 35 R&D Progress 35 Vaccine to Target IFN-Alpha for Chronic Viral Infections, Dermatomyositis and Systemic Lupus Erythematosus - Drug Profile 39 Product Description 39 Mechanism of Action 39 R&D Progress 39 Dermatomyositis - Recent Pipeline Updates 42 Dermatomyositis - Dormant Projects 60 Dermatomyositis - Product Development Milestones 61 Featured News & Press Releases 61 Nov 09, 2015: Idera Pharmaceuticals Announces Initiation of Phase 2 Clinical Trial of IMO-8400 in Patients with Dermatomyositis 61 Oct 13, 2015: Corbus Pharmaceuticals to Present at the 14th Annual BIO Investor Forum 61 Aug 06, 2015: Corbus Pharmaceuticals to Present at the Canaccord Genuity Growth Conference on August 13, 2015 62 Jul 13, 2015: Corbus Pharmaceuticals Announces Dosing of First Patient in Phase 2 Clinical Trial of Resunab for the Treatment of Dermatomyositis 62 Jun 16, 2015: Neovacs initiates clinical program in Dermatomyositis 63 Jun 16, 2015: Neovacs initiates clinical program in Dermatomyositis 64 Jun 05, 2015: Corbus Pharmaceuticals Expands Clinical Development of Resunab With a Phase 2 Trial for the Treatment of Rare Disease Dermatomyositis 65 May 13, 2015: Neovacs granted 1.8 million euros in research tax credit 66 Aug 08, 2014: Idera Pharmaceuticals and The Myositis Association Join Forces to Advance the Clinical Development of a Novel TLR Antagonist, IMO-8400, for the Treatment of Myositis 66 Mar 13, 2014: Idera Pharmaceuticals Announces Expansion of Pipeline into Two Orphan Autoimmune Diseases 67 Appendix 68 Methodology 68 Coverage 68 Secondary Research 68 Primary Research 68 Expert Panel Validation 68 Contact Us 68 Disclaimer 69
List of Tables
Number of Products under Development for Dermatomyositis, H1 2016 7 Number of Products under Development by Companies, H1 2016 8 Comparative Analysis by Clinical Stage Development, H1 2016 9 Comparative Analysis by Early Stage Development, H1 2016 10 Products under Development by Companies, H1 2016 11 Dermatomyositis - Pipeline by F. Hoffmann-La Roche Ltd., H1 2016 12 Dermatomyositis - Pipeline by Hope Pharmaceuticals, Inc., H1 2016 13 Dermatomyositis - Pipeline by Idera Pharmaceuticals, Inc., H1 2016 14 Dermatomyositis - Pipeline by MedImmune, LLC, H1 2016 15 Dermatomyositis - Pipeline by Neovacs SA, H1 2016 16 Dermatomyositis - Pipeline by Novartis AG, H1 2016 17 Assessment by Monotherapy Products, H1 2016 18 Number of Products by Stage and Target, H1 2016 20 Number of Products by Stage and Mechanism of Action, H1 2016 22 Number of Products by Stage and Route of Administration, H1 2016 24 Number of Products by Stage and Molecule Type, H1 2016 26 Dermatomyositis Therapeutics - Recent Pipeline Updates, H1 2016 42 Dermatomyositis - Dormant Projects, H1 2016 60
List of Figures
Number of Products under Development for Dermatomyositis, H1 2016 7 Number of Products under Development by Companies, H1 2016 8 Assessment by Monotherapy Products, H1 2016 18 Number of Products by Targets, H1 2016 19 Number of Products by Stage and Top 10 Targets, H1 2016 19 Number of Products by Mechanism of Actions, H1 2016 21 Number of Products by Stage and Mechanism of Actions, H1 2016 21 Number of Products by Routes of Administration, H1 2016 23 Number of Products by Stage and Routes of Administration, H1 2016 23 Number of Products by Molecule Types, H1 2016 25 Number of Products by Stage and Molecule Types, H1 2016 25
Global CoQ10 market size was 687.2 tons in 2014 and is expected to reach 1,168 tons by 2020, growing at a CAGR of 9.2% from 2014 to 2020, according to a new study by Radiant Insights, Inc. Increasing scope in personal care applications is expected toRead More...
Global automotive electronics market size forecast is likely to reach USD 279.96 billion by 2020, as per a new research report by Radiant Insights, Inc. Growing application scope of these equipments is estimated to drive industry growth. Increasing iRead More...
Global Automated Test Equipment (ATE) market is expected to be valued at USD 4.48 billion by 2020, as per a new research report by Radiant Insights, Inc. Increasing design complexity coupled with need for effective testing is expected to drive the glRead More...
Global Bio polyethylene terephthalate (PET) market size is likely to be valued at USD 12.6 billion by 2020; as per a new research report by Radiant Insights, Inc. Growing preference of biopolymers in numerous applications coupled with favorable goverRead More...
Global amino acids market size is anticipated to be valued at USD 35.4 billion by 2022, as per a new research report by Radiant Insights, Inc. Increase in animal feed additive demand owing to regulate metabolism in livestock production owing to growiRead More...
Get your queries resolved from an industry expert. Request for a free product review before report purchase.
Toll Free: 1-888-928-9744
Email: [email protected]
Speak to the report author to design an exclusive study to serve your research needs.
A testimonial for service excellence represented in the form of BBB "A" Accreditation.
Your personal and confidential information is safe and secure.